Open AccessMitogen-Activated Protein Kinase Inhibitor Selumetinib Fails to Increase the Complete Response Rate of Radioactive Iodine Alone in High-Risk Differentiated Thyroid Cancer: Lessons From the Phase III ASTRA Study
Author(s) -
Marcia S. Brose,
Daniel A. Pryma,
Kate Newbold
Publication year - 2022
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.22.00556
Subject(s) - medicine , selumetinib , radioactive iodine , thyroid cancer , protein kinase a , oncology , endocrinology , kinase , cancer research , thyroid , cancer , pharmacology , biochemistry , colorectal cancer , kras , chemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom